Utility and Application of the VeriKine Human IFN-α Multi-Subtype Serum ELISA

Utility and Application of the VeriKine Human IFN-α Multi-Subtype Serum ELISA
Author Affiliation: 
PBL Assay Science


  • Systemic lupus erythematosus (SLE) and IFN-α
  • Virology and IFN-α
  • IFN-α and Pharmacodynamics (PD)
  • IFN-α as a marker of toxicology
  • Benefits of the VeriKine Human IFN-α Multi-subtype Serum ELISA Kit


(Click "Download" for a PDF of full report)


Generation of type I interferons (IFNs) occurs downstream of a multitude of immunologic stimuli. The production of these cytokines can be either a positive prognostic, as in defensive immunity against a pathogenic insult, or a negative prognostic, as in promotion of autoimmunity. In humans, the designation “IFN−α” is used to represent a family of proteins comprised of at least 12 highly homologous protein subtypes that exhibit diverse biologic activities. IFN−α can be used as a therapeutic agent in disease treatment regimens, as a downstream readout of the effectiveness of several drug therapies currently in the pipeline, and as a marker of pathology in human clinical and preclinical studies. The necessity of having a simple, cost-effective, and highly reproducible assay for detecting IFN−α is unquestionable. However, the requirements of such an assay are complicated by the need to simultaneously detect not just one, but numerous subtypes of IFN−α proteins. Of the various medium- to high-throughput assays available that may be useful in such efforts, the VeriKine Human Interferon Alpha Serum enzyme linked immuno-sorbent assay (ELISA) stands out for its ease of use, sensitivity, reproducibility, and ability to simultaneously detect multiple IFN−α subtypes. The application of this assay to a variety of R&D and clinical trial settings is described below, followed by an overview of the unique methodological benefits of this assay.



Find your lot-specific Certificate of Analysis here!

Finding the right biomarker detection service to meet your project needs just got easier...

Sign up for our email list to be kept up-to-date on the latest product releases and company news!

Go to top